Review the Minoxidil / Finasteride source preparation, its listed specifications and the details your practice should confirm with the pharmacy.
For product identification and informed clinic review. No patient checkout is provided.
Optimal lists two Minoxidil / Finasteride entries with 5% / 0.1% and 60 mL. One explicitly names a solution; the other names a bottle without a dosage form. Confirm whether they refer to the same preparation.
Listed package: 60 mL — two source entries. Confirm the complete formulation, ingredient identities, percentage basis, dosage form, labeling and current pharmacy requirements. Source specifications are not application or dosing instructions.
Explore source listing2 source entries. Open the pharmacy to review its listings and confirmation notes.
| Source preparation / review note | Listed amount / specification | Package |
|---|---|---|
| Minoxidil 5% Finasteride 0.1% SolutionSolution explicitly named; confirm vehicle, percentage basis and whether duplicated by row 90 | 5% / 0.1% — confirm component basis | 60 mL |
| Minoxidil/Finasteride 5%/0.1%Dosage form not explicit in this entry; verify identity and potential overlap with the solution listing | 5% / 0.1% — confirm component basis | 60 mL bottle |
Review the exact product with the responsible pharmacy before submitting an order.
Check the ingredient name and its complete specification.
Review product-specific evidence and regulatory information.
Confirm missing or conflicting fields with the pharmacy.
Any further action depends on the exact product and applicable requirements.
CoreLink does not prescribe or dispense. Reference listings are not offers to supply products.
The treating clinician determines suitability and prescribing. Review the exact preparation’s labeling and pharmacy information.
The two entries share ingredient names and numeric fields, but that does not establish equivalence. Confirm the complete vehicle, percentage basis, exact labeling and preparation identity.
FDA states that there is no FDA-approved topical finasteride formulation and describes reports of systemic adverse effects and inadvertent transfer to others. A topical formulation should not be presented as free of systemic risk. This alert does not confirm that the two source entries are equivalent. FDA: compounded topical finasteride safety alert
Compounded drugs are not FDA-approved and do not undergo FDA premarket review for safety, effectiveness or quality. FDA: compounded drug information
Sources checked October 19, 2026. This page provides product information, not diagnosis, treatment selection, dosing or administration instructions.
No equivalence is established by matching ingredients, percentages or package size. One explicitly names a solution; verify dosage form, vehicle, ingredient specification, labeling and whether the listings duplicate one preparation.
No. A source entry does not establish approval, safety, effectiveness, current availability or eligibility. Review the exact preparation and current requirements with the responsible pharmacy.
No. Ingredient concentration, total content and package volume are separate specifications. This page gives no dosing, preparation or administration instructions.
No. Verify the exact product and its regulatory status. A compounded preparation is not FDA-approved, and a reference to an approved product does not establish equivalence.
A shared ingredient name or numerical value does not establish equivalence. Confirm the complete ingredient form, formulation, route and product labeling.
Ask for the exact ingredient identity, full formulation, strength units, dosage form, route, package, current labeling and applicable requirements. Resolve missing or conflicting information.
No. These pages provide reference information and no patient checkout. Patients should discuss treatment with their treating clinician.
Email info@corelinkpharm.com for platform questions. Contact the responsible pharmacy for preparation-specific information.
Contact CoreLink for account information. Ask the pharmacy about exact product specifications and eligibility.